Company GENFIT Euronext Paris

Equities

GNFT

FR0004163111

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sector Other Biotechnology & Medical Research

Inactive Instrument

End-of-day quote Euronext Paris Other stock markets
- ^PTS	-

May. 10	European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading; End Week Up Nearly 3%	MT
May. 08	European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Wednesday Trading	MT

GENFIT is a biopharmaceutical company in late-stage development focused on the discovery and development of innovative therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, in particular due to a lack of approved treatments. GENFIT is a leading innovator in the field of nuclear receptor-based drug discovery with a rich history and a solid scientific heritage spanning nearly two decades.

The company has offices in Lille, Paris, Zurich and Cambridge, MA (USA).

EUR in Million	2022	Weight	2023	Weight	Delta
Research and Development of Innovative Medicines and Diagnostic Solutions 100.0 %	20	100.0 %	29	100.0 %	+41.45%

EUR in Million	2022	Weight	2023	Weight	Delta
France 100.0 %	20	100.0 %	29	100.0 %	+41.45%

Managers	Title	Age	Since
Pascal Prigent CEO	Chief Executive Officer	56	18-04-30
Jean-François Mouney FOU	Founder	68	99-08-31
Thomas Baetz DFI	Director of Finance/CFO	50	21-04-21
John Brozek CTO	Chief Tech/Sci/R&D Officer	47	-
Stefanie Magner CMP	Compliance Officer	43	15-12-31
Pascal Caisey COO	Chief Operating Officer	56	19-08-31
Carol L. Addy CTO	Chief Tech/Sci/R&D Officer	64	19-09-08
Meriam Kabbaj CTO	Chief Tech/Sci/R&D Officer	50	22-11-30
Dean Hum CTO	Chief Tech/Sci/R&D Officer	61	99-12-31
Jean-Christophe Marcoux IRC	Investor Relations Contact	47	14-12-31

Members of the board	Title	Age	Since
Jean-François Tiné BRD	Director/Board Member	67	21-03-03
Jean-François Mouney FOU	Founder	68	99-08-31
Florence Séjourné FOU	Founder	52	99-09-14
Xavier Guille des Buttes BRD	Director/Board Member	82	06-10-17
Catherine Larue BRD	Director/Board Member	68	17-06-15
Anne-Hélène Monsellato BRD	Director/Board Member	56	17-06-15
Katherine Kalin BRD	Director/Board Member	61	20-07-06
Eric Baclet BRD	Director/Board Member	64	20-07-06

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	49,834,983	43,212,891 ( 86.71 %)	0	86.71 %

Name	Equities	%	Valuation
IPSEN 7.997 %	3,985,239	7.997 %	14 M PTS
Tang Capital Management LLC 4.917 %	2,450,404	4.917 %	9 M PTS
Biotech Avenir SAS 3.790 %	1,888,618	3.790 %	7 M PTS
Universite de Lille II Foundation 1.307 %	651,250	1.307 %	2 M PTS
Sunny Asset Management SA 0.2408 %	120,000	0.2408 %	432 864 PTS
Jean-François Mouney 0.0935 %	46,594	0.0935 %	168 074 PTS
Meeschaert Asset Management SA 0.0761 %	37,911	0.0761 %	136 753 PTS
Ecofi Investissements SA 0.0723 %	36,042	0.0723 %	130 011 PTS
OFI Invest Asset Management SA 0.0625 %	31,128	0.0625 %	112 285 PTS
Pascal Prigent 0.0616 %	30,708	0.0616 %	110 770 PTS

Name	Equities	%	Valuation
Tang Capital Management LLC 0.9621 %	479,441	0.9621 %	2 M PTS
Morgan Stanley & Co. International Plc 0.0617 %	30,763	0.0617 %	109 516 PTS
Millennium Management LLC 0.0568 %	28,310	0.0568 %	100 784 PTS
Old Mission Capital LLC 0.0249 %	12,428	0.0249 %	44 244 PTS
UBS Securities LLC 0.002282 %	1,137	0.002282 %	4 048 PTS
Optiver Holding BV 0.001932 %	963	0.001932 %	3 428 PTS
RhumbLine Advisers LP 0.001360 %	678	0.001360 %	2 414 PTS
Qube Research & Technologies Ltd. (France) 0.000197 %	98	0.000197 %	349 PTS

Genfit SA

Parc Eurasante 885, Avenue Eugène Avinée

59120, Loos

+33 3 20 16 40 00

http://www.genfit.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+17.96%	44.96B
IQVIA HOLDINGS INC.	+1.17%	42.65B
LONZA GROUP AG	+48.77%	41.85B
CELLTRION, INC.	-4.27%	29.04B
ICON PUBLIC LIMITED COMPANY	+11.42%	26.08B
ALNYLAM PHARMACEUTICALS, INC.	-21.39%	19.03B
BIO-TECHNE CORPORATION	+4.86%	12.75B
MEDPACE HOLDINGS, INC.	+27.29%	12.06B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.50%	11.75B

Other Biotechnology & Medical Research